ArticleTranslational vision science & technology2026
Enhancing Diagnostic Precision in Fuchs Dystrophy: Comparative Evaluation of REVO HR and FC130 OCT Systems.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the diagnostic performance of two anterior segment optical coherence tomography devices, REVO FC130 and REVO HR, in patients with Fuchs endothelial corneal dystrophy (FECD). Methods: This prospective cross-sectional study included 33 patients with FECD. Each patient was imaged with both devices. Eleven corneal features were graded independently by two evaluators. A third grader resolved disagreements. Agreement between graders and between devices was quantified by calculating the proportion of concordant assessments, including agreement for both detected and non-detected features, with corresponding 95% confidence intervals. Results: REVO HR provided better visualization of key corneal structures, including Descemet's membrane, Bowman's layer, and hyperreflective basal changes. Hyperreflective basal features were detected 11 times more often with REVO HR. Bowman's layer was identified 2.06 times more frequently with REVO HR compared to REVO FC130. Interoperator agreement was high for REVO HR (PropOverall ≥ 0.97 in 10 of 11 features). FC130 showed lower and more variable agreement, especially in low-contrast regions. Interdevice comparisons indicated systematic differences in detection capability. Conclusions: REVO HR showed higher sensitivity and reproducibility in detecting corneal microstructural changes in FECD. Improved image resolution allows better identification of subtle abnormalities, which may support more accurate disease staging and better timing of surgical intervention. For follow-up, the same OCT device should be used consistently. Translational Relevance: This study demonstrates that improved OCT resolution enhances detection of corneal microstructural abnormalities in Fuchs endothelial corneal dystrophy, improving diagnostic precision, disease staging, and clinical decision-making in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.